DEFA14A: Vincerx Pharma and Oqory Announce Promising Data for TROP2 Antibody Drug Conjugate and Proposed Strategic Merger

Vincerx Pharma and Oqory, Inc. highlight positive Phase 1a/1b data for Oqory's anti-TROP2 ADC, OQY-3258, and discuss their proposed strategic merger to advance the drug into Phase 3 trials.

Summary

• Vincerx Pharma and Oqory, Inc. announced promising Phase 1a/1b data for Oqory's anti-TROP2 ADC, OQY-3258, in patients with solid tumors.
• The companies are planning a strategic merger to advance OQY-3258 into global Phase 3 trials and build a differentiated ADC pipeline.
• OQY-3258, also known as ESG401, is being evaluated in three clinical trials, including two Phase 3 studies in breast cancer.
• As of August 2024, the Phase 1a/1b study had enrolled approximately 150 patients, showing promising preliminary results in multiple breast cancer subtypes.
• In previously untreated TNBC patients (n=35), a recent data cut from January 2025 showed an improved confirmed ORR of 80%, with median DOR and PFS still not reached.
• In late-stage TNBC patients (n=37), the confirmed ORR was 27% and DCR was 62%, with 6-month DOR and PFS rates of 39% and 25%, respectively.
• In HR+/HER2breast cancer patients (n=58), the confirmed ORR was 39%, DCR was 78%, and 6-month DOR and PFS rates of 70% and 55%, respectively, with a median PFS of 7.4 months.
• OQY-3258 demonstrated meaningful activity in patients with brain metastases, reporting an intracranial ORR of 41% (n=17).
• The drug has shown a favorable safety profile, with manageable hematologic toxicities and a lower incidence of severe off-target toxicity compared to other TROP2 therapies.
• Oqory equity holders are expected to own approximately 95% of the combined entity, and Vincerx equity holders are expected to hold approximately 5%.
• The proposed merger provides for a minimum fully diluted equity value of $13.66 million for existing Vincerx stockholders at closing.
• A concurrent private offering of Vincerx equity securities of at least $20 million is planned as a condition to the closing of the merger.
• Oqory-designated investors will provide interim financing to Vincerx of $1.5 million in two tranches.

Sentiment

Score: 8

Explanation: The document presents promising clinical data and a strategic merger plan, suggesting a positive outlook for both companies and the development of OQY-3258. The high ORR and favorable safety profile contribute to the positive sentiment.

Positives

• OQY-3258 demonstrates high ORR in previously untreated TNBC patients.
• The drug shows activity in patients with brain metastases.
• OQY-3258 has a favorable safety profile compared to other TROP2 ADCs.
• The merger aims to accelerate the development of OQY-3258 and build a pipeline of next-generation ADCs.
• Interim financing of $1.5 million will be provided to Vincerx by Oqory-designated investors.

Negatives

• Vincerx equity holders are expected to hold only approximately 5% of the combined entity after the merger.
• The merger is contingent on several conditions, including completion of a $20 million financing and stockholder approval.

Risks

• The merger is subject to customary closing conditions, including regulatory approvals and stockholder approval.
• The entry into a definitive merger agreement is contingent on satisfactory completion of due diligence by both companies.
• The companies' capital requirements and the availability and sufficiency of capital are potential risks.
• Clinical development of the product candidates is subject to inherent risks.
• General economic, financial, legal, political, and business conditions could impact the merger and development plans.

Future Outlook

The companies aim to advance OQY-3258 into global Phase 3 trials and build a differentiated ADC pipeline by leveraging their combined expertise. The merger is expected to close subject to customary conditions, including regulatory and stockholder approvals, and the completion of a minimum $20 million financing.

Management Comments

• Michael King, CEO of Oqory, stated that the compelling clinical activity highlights the potential of OQY-3258 to address significant unmet needs in TROP2-expressing tumors.
• Raquel Izumi, Ph.D., Acting CEO of Vincerx, added that the merger reflects their commitment to develop transformative therapies for patients with cancer.

Industry Context

The announcement highlights the growing interest in antibody-drug conjugates (ADCs) as a targeted cancer therapy. The focus on TROP2 as a target is consistent with industry trends, as several companies are developing ADCs targeting this protein. The favorable safety profile of OQY-3258, if confirmed in later-stage trials, could provide a competitive advantage over existing TROP2-directed therapies.

Comparison to Industry Standards

• The reported ORR of 80% in previously untreated TNBC patients for OQY-3258 is promising compared to existing treatments like Trodelvy (sacituzumab govitecan), which has shown ORRs in the range of 30-40% in similar patient populations.
• The intracranial ORR of 41% in patients with brain metastases suggests potential advantages over existing therapies, as brain metastases are often difficult to treat.
• The favorable safety profile, with no Grade 3 rash or interstitial lung disease/pneumonitis observed, differentiates OQY-3258 from some other TROP2 ADCs that have been associated with these toxicities.
• Companies like Gilead (Trodelvy) and Daiichi Sankyo (Enhertu) are key players in the ADC space, and the success of OQY-3258 will depend on its ability to demonstrate superior efficacy and safety in Phase 3 trials.

Stakeholder Impact

• Shareholders of Vincerx will see a significant dilution in ownership, but may benefit from the potential success of OQY-3258.
• Patients with TROP2-expressing tumors could benefit from a new, potentially more effective and safer treatment option.
• Employees of both companies may experience changes as a result of the merger.

Next Steps

• Satisfactory completion of due diligence by Vincerx and Oqory.
• Negotiation and entry into a definitive merger agreement.
• Completion of the interim financing for Vincerx.
• Commitments by investors for the concurrent financing.
• Regulatory approvals and stockholder approval from both parties.
• Completion of the minimum $20 million financing.
• Closing of the merger.

Key Dates

Keywords

OQY-3258, ADC, TROP2, Vincerx, Oqory, Merger, Breast Cancer, Clinical Trials, Oncology, Pharmaceuticals